Premium
Successful treatment for obsessive‐compulsive disorder with addition of low‐dose risperidone to fluvoxamine: Implications for plasma levels of catecholamine metabolites and serum brain‐derived neurotrophic factor levels
Author(s) -
YOSHIMURA REIJI,
KANEKO SACHIKO,
SHINKAI KOJI,
NAKAMURA JUN
Publication year - 2006
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/j.1440-1819.2006.01519.x
Subject(s) - fluvoxamine , risperidone , homovanillic acid , serotonergic , psychology , dopaminergic , medicine , brain derived neurotrophic factor , endocrinology , neurotrophic factors , dopamine , pharmacology , serotonin , schizophrenia (object oriented programming) , psychiatry , receptor , fluoxetine
The authors report on the successful treatment of obsessive‐compulsive disorder (OCD) in three patients with the addition of risperidone to ongoing fluvoxamine treatment. Plasma homovanillic acid (HVA), but not 3‐methoxy‐4‐hydroxyphenylglycol (MHPG) levels decreased after risperidone administration, and plasma levels of fluvoxamine did not change. In addition, serum brain‐derived neurotrophic factor (BDNF) levels were not altered after the recovery from obsessive‐compulsive symptoms, indicating that serum BDNF levels might not predict the patient’s response to risperidone treatment. Taken together, a combination treatment of risperdone and fluvoxamine might improve obsessive‐compulsive symptoms. In short, fluvoxamine enhances the activity of the serotonergic system by inhibiting serotonin transporters, and risperidone decreases that of the dopaminergic system by blocking D 2 receptors.